Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News

Marinus Pharmaceuticals Inc MRNS closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits.

The stock moved mostly on sympathy for SAGE Therapeutics Inc SAGE, a biotech peer that released positive clinical data on its brexanolone treatment for major depressive disorder and subsequently surged 70 percent.

Street analysts expect the drug to advance to Phase 3 studies, eventually secure regulatory approval and potentially prove efficacious in treating Parkinson’s and essential tremor.

Sage’s progress was well interpreted by Marinus investors, who back a similar pipeline to treat postpartum depression and epilepsy. Marinus’ ganaxolone, a GABA modulator akin to SAGE-217, is in Phase 2 development for four separate trials.

At the time of publication, Marinus shares were set to open up 2.4 percent at $8.85, while Sage was up 1.7 percent at $158.99.

Related Links:

Hertz Moving In Sympathy With Avis Budget

5 Dry Bulk Shipping Stocks Moving In Sympathy With Diana Containerships Outsized Move

Hasbro, Mattel Just Proved That Sympathy Plays Don't Always Pay Off

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Health CareTrading IdeasGeneralganaxoloneSAGE-217
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!